We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Wockhardt CEO: Company to Resolve ‘Minor’ Form 483 Issues With FDA
Wockhardt CEO: Company to Resolve ‘Minor’ Form 483 Issues With FDA
Wockhardt’s CEO Habil Khorakiwala has characterized the FDA’s recent findings of nine Form 483 observations at its manufacturing plant in Shendra, India as minor, and predicted that the agency’s concerns would be resolved within a few months.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor